Juno Bio, a women’s health company focused on precision vaginal microbiome testing and multi-omics, has opened a sequencing lab built entirely for women’s health in Oakland, California, and raised $3.8 million in funding. Investors include Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.
Using next-generation sequencing, Juno Bio’s platform delivers a clinically actionable view of vaginal health. Its new vaginal microbiome and STI test, processed in the company’s own CLIA-certified lab, analyzes approximately 10,000 bacteria and fungi along with four common STIs. Unlike traditional tests that focus on a limited set of pathogens, the platform can identify microbes associated with co-infections, subclinical conditions, and broader microbiome patterns – helping clarify likely drivers of concerns such as bacterial vaginosis, yeast infections, aerobic vaginitis, cytolytic vaginosis, and estrogen-related changes.
The data underscores the diagnostic gap the company is targeting. According to Juno Bio, prior to using its test, 67.5% of customers had been incorrectly diagnosed – whether misdiagnosed, underdiagnosed, or overdiagnosed – and only 13% had been successfully treated. Roughly half of users experience co-infections, which are often missed by conventional testing but can significantly affect treatment outcomes.
Since its founding, Juno Bio has sold more than 20,000 tests and built one of the largest repositories of vaginal microbiome data, evolving from a wellness test into a clinical platform with pharmaceutical R&D partnerships, telehealth and pharmacy integrations, and a network of medical advisors including Anna Powell, MD, of Johns Hopkins.
“Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women’s health,” said founder and CEO Hana Janebdar. “This next chapter is about scaling that work, expanding access to more actionable care, and continuing to close the gender health gap.”
“The vaginal microbiome is still one of the least understood systems in the body at a clinical scale. With our lab, we’re starting to build a measurement standard that clinicians can actually use,” said founder and CSO Leighton Turner, PhD.
The new clinically actionable test builds on Juno Bio’s original wellness test with physician ordering and review and CLIA-certified lab processing. It is currently available in 46 U.S. states, with further expansion planned.
